BRD9 and hematopoietic and lymphoid system neoplasm: The main theme of the current study is BRD9 as a therapeutic, druggable target in a select panel of heme malignancies that includes and extends beyond AML, previously identified as exhibiting BRD9 dependency and thus serving as a positive reference for comparison with the other blood cancers we investigated.